HUE035247T2 - Szilárd diszperzió - Google Patents

Szilárd diszperzió Download PDF

Info

Publication number
HUE035247T2
HUE035247T2 HUE12809373A HUE12809373A HUE035247T2 HU E035247 T2 HUE035247 T2 HU E035247T2 HU E12809373 A HUE12809373 A HU E12809373A HU E12809373 A HUE12809373 A HU E12809373A HU E035247 T2 HUE035247 T2 HU E035247T2
Authority
HU
Hungary
Prior art keywords
solid dispersion
dispersion
yloxy
triazolo
dimethyl
Prior art date
Application number
HUE12809373A
Other languages
English (en)
Inventor
David Shank Fry
Christopher M Lindemann
Michael Preigh
Corey Jay Bloom
Christopher Donovan Craig
Devon Brevard Dubose
Jeff Gautschi
Dan Smithey
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of HUE035247T2 publication Critical patent/HUE035247T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Description

Description
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
[0001] A solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihy-drooxazol-2-yl)quinazoline-4,6-diamine is provided herein. Also, a pharmaceutical composition comprising a solid dispersion ofN4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol -2-yl)quina-zoline-4,6-diamine is provided herein.
DESCRIPTION OF THE STATE OF THE ART
[0002] Λ/4-(4-([1,2,4]Triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quina- zoline-4,6-diamine (also called "ARRY-380"), which has the structure:
is a selective ErbB2 (HER2) inhibitor described in WO 2007/059257. Λ/4-(4-([1,2,4]Triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine has been tested in human clinical trials for hyperproliferative diseases, particularly cancer (see Koch, Kevin. "ARRY-380: A Selective, Oral HER2 Inhibitor for the Treatment of Solid Tumors." American Association of Cancer Research 102nd Annual Meeting, April 3, 2011 ; which may also be found at: http://www.arraybiopharma.com/_documents/Publication/PubAttachment462.pdf).
[0003] A powder-in-capsule ("PIC") composition of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphe-nyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine was prepared and administered to patients with cancer, and the overall inter-patient variability for area under the plasma concentration-time curve ("AUC") and maximum concentration ("Cmax") was moderate to high.
[0004] Vasconcelos et al.: "Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs", Drug Discovery Today, Elsevier, RAH WAY, NJ, US, vol. 12, no. 23-24, 30 October 2007, pages 1068-1075, ISSN: 1359-6446, is a general review about the use of solid dispersions in pharmaceutical dosage forms.
[0005] There remains a need to prepare a pharmaceutical composition containing Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine that minimizes inter-patient variability of pharmacokinetics.
SUMMARY OF THE INVENTION
[0006] A solid dispersion comprising Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is described herein.
[0007] A pharmaceutical composition comprising Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphe-nyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is described herein.
[0008] A pharmaceutical composition comprising a solid dispersion of/\/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is described herein.
[0009] A pharmaceutical composition comprising a solid dispersion of amorphous Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is described herein.
[0010] Solid dispersions and pharmaceutical compositions for use in the treatment of a disease, in particular cancer, are also described herein.
BRIEF DESCRIPTION OF THE FIGURES
[0011]
Figure 1 shows a comparison of XRPD scans of amorphous 30% solid dispersions and crystalline Λ/4-(4-([1,2,4] triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, with a close up of the amorphous solid dispersions.
Figure 2 shows a dissolution profile of a 30% solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-meth-ylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine.
Figure 3 shows a dissolution profile of a 30% solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-meth-ylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine.
Figure 4 shows a dissolution profile of a 30% solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-meth-ylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine.
Figure 5 shows a dissolution profile of a 30% solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-meth-ylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine.
Figure 6 shows a dissolution profile of a 30% solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-meth-ylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine.
Figure 7 shows a comparison of XRPD scans of amorphous 60% solid dispersions and crystalline Λ/4-(4-([1,2,4] triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, with a close up of the amorphous solid dispersions.
Figure 8 shows a dissolution profile of a 60% solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-meth-ylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine.
Figure 9 shows a dissolution profile of a 60% solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-meth-ylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine.
Figure 10 shows a dissolution profile of a 60% solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine.
Figure 11 shows a dissolution profile of a 60% solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine.
Figure 12 shows a dissolution profile of a 60% solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine.
Figure 13 shows a dissolution comparison of a solid dispersion tablet and a crystalline PIC composition.
DETAILED DESCRIPTION OF THE INVENTION
[0012] Reference will now be made in detail to certain embodiments, examples of which are illustrated herein. While enumerated embodiments will be described, it will be understood that they are not intended to limit the invention to those embodiments. On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents, which may be included within the scope of the present invention as defined by the claims. One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. The present invention is in no way limited to the methods and materials described. In the event that one or more of the incorporated literature and similar materials differs from or contradicts this application, including but not limited to defined terms, term usage, described techniques, or the like, this application controls.
DEFINITIONS
[0013] The term "about" is used herein to mean approximately, in the region of, roughly, or around. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term "about" is used herein to modify a numerical value above and below the stated value by a variance of 20%.
[0014] As used herein, the recitation of a numerical range for a variable is intended to convey that the invention may be practiced with the variable equal to any of the values within that range. Thus, for a variable that is inherently discrete, the variable can be equal to any integer value of the numerical range, including the end-points of the range. Similarly, for a variable that is inherently continuous, the variable can be equal to any real value of the numerical range, including the end-points of the range. As an example, a variable that is described as having values between 0 and 2, can be 0, 1 or 2 for variables that are inherently discrete, and can be 0.0, 0.1, 0.01, 0.001, or any other real value for variables that are inherently continuous.
[0015] The term "amorphous" means a solid in a solid state that is a non-crystalline state. Amorphous solids generally possess crystal-like short range molecular arrangement, but no long range order of molecular packing as found in crystalline solids. The solid state form of a solid may be determined by polarized light microscopy, x-ray powder diffraction ("XRPD"), differential scanning calorimetry ("DSC"), or other standard techniques known to those of skill in the art. [0016] The phrase "amorphous solid dispersion" means a solid comprising a drug substance and a dispersion polymer. The amorphous solid dispersion discussed herein comprises amorphous Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3- methylphenyl)-/V6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a dispersion polymer, wherein the amorphous solid dispersion contains Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine in a substantially amorphous solid state form. In certain embodiments, the substantially amorphous solid state form means that the Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphe-nyl)-/V6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine component in the amorphous solid dispersion is at least 80% amorphous Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxa-zol-2-yl)quinazoline-4,6-diamine. In certain embodiments, the substantially amorphous solid state form means that the Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine component in the amorphous solid dispersion is at least 85% amorphous Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine. In certain embodiments, the substantially amorphous solid state form means that the Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphe-nyl)-/V6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine component in the amorphous solid dispersion is at least 90% amorphous Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxa-zol-2-yl)quinazoline-4,6-diamine. In certain embodiments, the substantially amorphous solid state form means that the Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine component in the amorphous solid dispersion is at least 95% amorphous Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine.
[0017] The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by abnormal or unregulated cell growth. A "tumor" comprises one or more cancerous cells. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (e.g., epithelial squamous cell cancer), lung cancer including small cell lung cancer, non-small cell lung cancer ("NSCLC"), adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, brain, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, skin cancer, including melanoma, as well as head and neck cancer.
[0018] The phrase "dispersion polymer" means a polymer that allows for Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine to be dispersed throughout such that a solid dispersion may form. The dispersion polymer is preferably neutral or basic. The dispersion polymer may contain a mixture of two or more polymers. Examples of dispersion polymers include, but are not limited to, vinyl polymers and copolymers, vinylpyrrolidine vinylacetate copolymer ("PVP-VA"), polyvinyl alcohols, polyvinyl alcohol polyvinyl acetate copolymers, polyvinyl pyrrolidine ("PVP"), acrylate and methacrylate copolymers, methylacrylicacid methyl methacrylate copolymer (such as Eudragit®), polyethylene polyvinyl alcohol copolymers, polyoxyethylene-polyoxypropylene block copolymers (also referred to as poloxamers), graft copolymer comprised of polyethylene glycol, polyvinyl caprolactam and polyvinyl acetate (such as Soluplus®), cellulosic polymers, such as hydroxypropyl methyl cellulose acetate (ΉΡ-MCA"), hydroxypropyl methyl cellulose ("HPMC"), hydroxypropyl cellulose ("HPC"), methyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl cellulose, hydroxyethyl cellulose acetate, and hydroxyethyl ethyl cellulose, hydroxypropyl methyl cellulose acetate succinate ("HPMCAS"), hydroxypropyl methyl cellulose phthalate ("HPMCP"), carboxymethylethyl cellulose ("CMEC"), cellulose acetate phthalate ("CAP"), cellulose acetate succinate ("CAS"), hydroxypropyl methyl cellulose acetate phthalate ("HPMCAP"), cellulose acetate trimellitate ("CAT"), hydroxypropyl methyl cellulose acetate trimellitate ("HPMCAT"), and carboxymethylcellulose acetate butyrate ("CMCAB"), and the like.
[0019] The term "mammal" means a warm-blooded animal that has or is at risk of developing a disease described herein and includes, but is not limited to, guinea pigs, dogs, cats, rats, mice, hamsters, and primates, including humans. [0020] The phrase "pharmaceutically acceptable" indicates that the substance or composition is compatible chemically and/or toxicologically, with the other ingredients comprising a composition, and/or the mammal being treated therewith. [0021] The phrase "pharmaceutically acceptable salt," as used herein, refers to pharmaceutically acceptable organic or inorganic salts of a compound described herein.
[0022] The phrase "solid dispersion" means a system in a solid state comprising at least two components, wherein one component is dispersed throughout the other component. The solid dispersion discussed herein comprises one component of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine dispersed throughout another component, particularly a dispersion polymer.
[0023] The phrase "spray drying" means processes involved in breaking up liquid mixtures into small droplets (atomization) and rapidly removing solvent from the mixture in a spray drying apparatus where there is a strong driving force for evaporation of solvent from the droplets. The phrase spray drying is used conventionally and broadly. Spray drying processes and spray drying equipment are described generally in Perry, Robert H., and Don W. Green (eds.). Perry’s Chemical Engineers’ Handbook. New York: McGraw-Hill, 2007 (8th edition).
[0024] The phrases "therapeutically effective amount" or "effective amount" mean an amount of a compound described herein that, when administered to a mammal in need of such treatment, sufficient to (i) treat or prevent the particular disease, condition, or disorder, (ii) attenuate, ameliorate, or eliminate one or more symptoms of the particular disease, condition, or disorder, or (iii) prevent or delay the onset of one or more symptoms of the particular disease, condition, or disorder described herein. The amount of a compound that will correspond to such an amount will vary depending upon factors such as the particular com pound, disease condition and its severity, the identity (e.g., weight) of the mammal in need of treatment, but can nevertheless be routinely determined by one skilled in the art.
[0025] The terms "treat" or "treatment" refer to therapeutic, prophylactic, palliative or preventative measures. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (/.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder, as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.
SOLID DISPERSIONS AND PHARMACEUTICAL COMPOSITIONS
[0026] Provided herein is a solid dispersion comprising /V4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphe-nyl)-/V6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine.
[0027] The solid dispersions are generally prepared by dissolving the drug substance and the dispersion polymer in a suitable solvent to form a feed solution, and then the feed solution may be spray dried to form the solid dispersion (and remove the solvent). Spray drying is a known process. Spray drying is generally performed by dissolving Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and the dispersion polymer in a suitable solvent to prepare a feed solution. The feed solution may be pumped through an atomizer into a drying chamber. The feed solution can be atomized by conventional means known in the art, such as a two-fluid sonicating nozzle, a pressure nozzle, a rotating nozzle and a two-fluid non-sonicating nozzle. Then, the solvent is removed in the drying chamber to form the solid dispersion. A typical drying chamber uses hot gases, such as forced air, nitrogen, nitrogen-enriched air, or argon to dry particles. The size of the drying chamber may be adjusted to achieve particle properties or throughput.
[0028] Although the solid dispersion are preferably prepared by conventional spray drying techniques, other techniques known in the art may be used, such as melt extrusion, freeze drying, rotary evaporation, drum drying or other solvent removal processes.
[0029] In one example, a process of preparing a solid dispersion is described, comprising: (a) dissolving Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a dispersion polymer in a suitable solvent; and (b) evaporating the solvent to form the solid dispersion.
In a further example, the evaporation of the solvent in step (b) is performed by spray drying, melt extrusion, freeze drying, rotary evaporation, drum drying or other solvent removal processes.
[0030] In certain embodiments, the dispersion polymer is selected from PVP-VA, methylacrylic acid methyl methacrylate copolymer, HPMCP, CAP, HPMCAS and HPMC and mixtures thereof. In certain embodiments, the dispersion polymer is selected from PVP-VA, methylacrylic acid methyl methacrylate copolymer, HPMCP, CAP, HPMCAS and HPMC. In certain embodiments, the dispersion polymer is selected from PVP-VA, Eudragit® L100, HPMCP H-55, CAP, HPMCAS Grade M, HPMC and mixtures thereof. In certain embodiments, the dispersion polymer is selected from PVP-VA, Eudragit® L100, HPMCP H-55, CAP, HPMCAS Grade M and HPMC.
[0031] In certain embodiments, the dispersion polymer is selected from PVP-VA, methylacrylic acid methyl methacrylate copolymer, HPMCP, CAP and HPMCAS, and mixtures thereof. In certain embodiments, the dispersion polymer is selected from PVP-VA, methylacrylic acid methyl methacrylate copolymer, HPMCP, CAP and HPMCAS. In certain embodiments, the dispersion polymer is selected from PVP-VA, Eudragit® L100, HPMCP H-55, CAP and HPMCAS Grade M, and mixtures thereof. In certain embodiments, the dispersion polymer is selected from PVP-VA, Eudragit® L100, HPMCP H-55, CAP and HPMCAS Grade M.
[0032] In certain embodiments, the dispersion polymer is selected from PVP-VA, methylacrylic acid methyl methacrylate copolymer, HPMCP, CAP and HPMC, and mixtures thereof. In certain embodiments, the dispersion polymer is selected from PVP-VA, methylacrylic acid methyl methacrylate copolymer, HPMCP, CAP and HPMC. In certain embodiments, the dispersion polymer is selected from PVP-VA, Eudragit® L100, HPMCP H-55, CAP and HPMC, and mixtures thereof. In certain embodiments, the dispersion polymer is selected from PVP-VA, Eudragit® L100, HPMCP H-55, CAP and HPMC.
[0033] In certain embodiments, the dispersion polymer is selected from PVP-VA, methylacrylic acid methyl methacr ylate copolymer, HPMCP and CAP, and mixtures thereof. In certain embodiments, the dispersion polymer is selected from PVP-VA, methylacrylic acid methyl methacrylate copolymer, HPMCP and CAP. In certain embodiments, the dispersion polymer is selected from PVP-VA, Eudragit® L100, HPMCP H-55 and CAP, and mixtures thereof. In certain embodiments, the dispersion polymer is selected from PVP-VA, Eudragit® L100, HPMCP H-55 and CAP.
[0034] In certain embodiments, the dispersion polymer is PVP-VA.
[0035] In certain embodiments, the dispersion polymer is methylacrylic acid methyl methacrylate copolymer. In certain embodiments, the dispersion polymer is Eudragit®. In certain embodiments, the dispersion polymer is Eudragit® L100. [0036] In certain embodiments, the dispersion polymer is HPMCP. In certain embodiments, the dispersion polymer is HPMCP H-55.
[0037] In certain embodiments, the dispersion polymer is CAP.
[0038] In certain embodiments, the dispersion polymer is HPMCAS. In certain embodiments, the dispersion polymer is HPMCAS Grade M.
[0039] In certain embodiments, the dispersion polymer is preferably neutral or basic. In certain embodiments, the dispersion polymer is selected from PVP-VA and HPMC. In certain embodiments, the dispersion polymer is HPMC. [0040] Suitable solvents are a solvent or mixture of solvents in which both Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and the dispersion polymer have adequate solubility (solubility greater than 1 mg/mL). A mixture of solvents may be used if each component of the solid dispersion (/.e., Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2- yl)quinazoline-4,6-diamine and dispersion polymer) require different solvents to obtain the desired solubility. The solvent may be volatile with a boiling point of 150°C or less. In addition, the solvent should have relatively low toxicity and be removed from the dispersion to a level that is acceptable to The International Committee on Harmonization ("ICH") guidelines. Removal of solvent to this level may require a subsequent processing step, such as tray drying. Examples of suitable solvents include, but are not limited to, alcohols, such as methanol ("MeOH"), ethanol ("EtOH"), n-propanol, isopropanol ("IPA") and butanol; ketones, such as acetone, methyl ethyl ketone ("MEK") and methyl isobutyl ketone; esters, such as ethyl acetate ("EA") and propyl acetate; and various other solvents, such as tetrahydrofuran ("THF"), acetonitrile ("ACN"), methylene chloride, toluene and 1,1,1-trichloroethane. Lower volatility solvents, such as dimethyl acetate or dimethylsulfoxide ("DMSO"), may be used. Mixtures of solvents with water may also be used, so long as the polymer and Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are sufficiently soluble to make the spray drying process practicable. Generally, due to the hydrophobic nature of low solubility drugs, non-aqueous solvents may be used, meaning the solvent comprises less than about 10 weight % water.
[0041] In certain examples, the suitable solvent is selected from MeOH and THF, and mixtures thereof. In certain examples, the suitable solvent is MeOH:THF solvent system of about 1:3. In certain examples, the suitable solvent is a 1:3 MeOH:THF solvent system.
[0042] In certain examples, the suitable solvent is selected from MeOH, THF and water, and mixtures thereof. In certain examples, the suitable solvent is selected from MeOH, THF and water. In certain examples, the suitable solvent is a THF:MeOH :water solvent system of about 80:10:10. In certain examples, the suitable solvent is a 80:10:10 THF:Me-OH:water solvent system. In certain examples, the suitable solvent is a THF:MeOH:water solvent system of about 82:8:10. In certain examples, the suitable solvent is a 82:8:10 THF:MeOH:water solvent system. In certain examples, the suitable solvent is a THF:MeOH:water solvent system of about 82.2:8.2:9.6. In certain examples, the suitable solvent is a 82.2:8.2:9.6 THF:MeOH:water solvent system.
[0043] In certain embodiments, the amount of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine in the solid dispersion ranges from about 0.1% to about 70% by weight relative to the dispersion polymer. In certain embodiments, the amount of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine in the solid dispersion ranges from 0.1% to 70% by weight relative to the dispersion polymer.
[0044] In certain embodiments, the amount of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine in the solid dispersion ranges from about 1 % to about 60% by weight relative to the dispersion polymer. In certain embodiments, the amount of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine in the solid dispersion ranges from 1 % to 60% by weight relative to the dispersion polymer.
[0045] In certain embodiments, the amount of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine in the solid dispersion ranges from about 5% to about 60% by weight relative to the dispersion polymer. In certain embodiments, the amount of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine in the solid dispersion ranges from 5% to 60% by weight relative to the dispersion polymer.
[0046] In certain embodiments, the amount of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine in the solid dispersion ranges from about 55% to about 65% by weight relative to the dispersion polymer. In certain embodiments, the amount of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine in the solid dispersion ranges from 55% to 65% by weight relative to the dispersion polymer. In certain embodiments, the amount of Λ/4-(4-([1,2,4] triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine in the solid dispersion is about 60% by weight relative to the dispersion polymer. In certain embodiments, the amount of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine in the solid dispersion is 60% by weight relative to the dispersion polymer.
[0047] In certain embodiments, the amount of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine in the solid dispersion ranges from about 25% to about 35% by weight relative to the dispersion polymer. In certain embodiments, the amount of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine in the solid dispersion ranges from 25% to 35% by weight relative to the dispersion polymer. In certain embodiments, the amount of Λ/4-(4-([1,2,4] triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine in the solid dispersion is about 30% by weight relative to the dispersion polymer. In certain embodiments, the amount of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine in the solid dispersion is 30% by weight relative to the dispersion polymer.
[0048] In certain embodiments, the amount of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine in the solid dispersion ranges from about 45% to about 55% by weight relative to the dispersion polymer. In certain embodiments, the amount of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine in the solid dispersion ranges from 45% to 55% by weight relative to the dispersion polymer. In certain embodiments, the amount of Λ/4-(4-([1,2,4] triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine in the solid dispersion is about 50% by weight relative to the dispersion polymer. In certain embodiments, the amount of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine in the solid dispersion is 50% by weight relative to the dispersion polymer.
[0049] In certain embodiments, the solid dispersion is an amorphous solid dispersion.
[0050] Another embodiment provides a pharmaceutical composition comprising a solid dispersion of Λ/4-(4-([1,2,4] triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a dispersion polymer, and a carrier or excipient.
[0051] Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel, Howard C., et al., Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro, Alfonso R., et al. Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005.
[0052] The pharmaceutical compositions may also include one or more additional components, such as buffers, dispersion agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug, i.e., a compound described herein or pharmaceutical composition thereof, or aid in the manufacturing of the pharmaceutical product, i.e., medicament (see Ansel; Gennaro; and Rowe above). The components of the pharmaceutical composition should be pharmaceutically acceptable. [0053] Certain embodiments provide a pharmaceutical composition comprising: (a) about 1 to about 70 weight % of a solid dispersion of /V4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphe-nyl)-/V6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; (b) about 0.1 to about 20 weight % of a disintegrant; (c) about 0.1 to about 25 weight % of an osmogen; (d) about 0.1 to about 10 weight % of a glidant; (e) about 0.1 to about 10 weight % of a lubricant; and (f) about 0.1 to about 25 weight % of a binder / diluent.
In a further embodiment, the pharmaceutical composition comprises: (a) 1 to 70 weight % of a solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; (b) 0.1 to 20 weight % of a disintegrant; (c) 0.1 to 25 weight % of an osmogen; (d) 0.1 to 10 weight % of a glidant; (e) 0.1 to 10 weight % of a lubricant; and (f) 0.1 to 25 weight % of a binder / diluent.
[0054] Certain embodiments provide a pharmaceutical composition comprising: (a) about 25 to about 60 weight % of a solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphe-nyl)-/V6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; (b) about 5 to about 15 weight % of a disintegrant; (c) about 15 to about 25 weight % of an osmogen; (d) about 0.1 to about 3 weight % of a glidant; (e) about 0.1 to about 3 weight % of a lubricant; and (f) about 10 to about 25 weight % of a binder / diluent.
In a further embodiment, the pharmaceutical composition comprises: (a) 25 to 60 weight % of a solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; (b) 5 to 15 weight % of a disintegrant; (c) 15 to 25 weight % of an osmogen; (d) 0.1 to 3 weight % of a glidant; (e) 0.1 to 3 weight % of a lubricant; and (f) 10 to 25 weight % of a binder / diluent.
[0055] Certain embodiments provide a pharmaceutical composition comprising: (a) about 40 to about 60 weight % of a solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphe-nyl)-/V6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; (b) about 5 to about 15 weight % of a disintegrant; (c) about 15 to about 25 weight % of an osmogen; (d) about 0.1 to about 3 weight % of a glidant; (e) about 0.1 to about 3 weight % of a lubricant; and (f) about 10 to about 25 weight % of a binder / diluent.
In a further embodiment, the pharmaceutical composition comprises: (a) 40 to 60 weight % of a solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; (b) 5 to 15 weight % of a disintegrant; (c) 15 to 25 weight % of an osmogen; (d) 0.1 to 3 weight % of a glidant; (e) 0.1 to 3 weight % of a lubricant; and (f) 10 to 25 weight % of a binder / diluent.
[0056] Certain embodiments provide a pharmaceutical composition comprising: (a) about 1 to about 70 weight % of a solid dispersion of /V4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphe-nyl)-/V6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; (b) about 0.1 to about 20 weight % of a disintegrant; (c) about 0.1 to about 25 weight % of an osmogen; (d) about 0.1 to about 10 weight % of a glidant; (e) about 0.1 to about 10 weight % of a lubricant; and (f) about 0.1 to about 25 weight % of a filler.
In a further embodiment, the pharmaceutical composition comprises: (a) 1 to 70 weight % of a solid dispersion of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; (b) 0.1 to 20 weight % of a disintegrant; (c) 0.1 to 25 weight % of an osmogen; (d) 0.1 to 10 weight % of a glidant; (e) 0.1 to 10 weight % of a lubricant; and (f) 0.1 to 25 weight % of a filler.
[0057] Certain embodiments provide a pharmaceutical composition comprising: (a) about 25 to about 60 weight % of a solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphe-nyl)-/V6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; (b) about 1 to about 10 weight % of a disintegrant; (c) about 15 to about 25 weight % of an osmogen; (d) about 0.1 to about 3 weight % of a glidant; (e) about 0.1 to about 3 weight % of a lubricant; and (f) about 10 to about 25 weight % of a filler.
In a further embodiment, the pharmaceutical composition comprises: (a) 25 to 60 weight % of a solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; (b) 1 to 10 weight % of a disintegrant; (c) 15 to 25 weight % of an osmogen; (d) 0.1 to 3 weight % of a glidant; (e) 0.1 to 3 weight % of a lubricant; and (f) 10 to 25 weight % of a filler.
[0058] Certain embodiments provide a pharmaceutical composition comprising: (a) about 40 to about 60 weight % of a solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphe-nyl)-/V6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; (b) about 1 to about 10 weight % of a disintegrant; (c) about 15 to about 25 weight % of an osmogen; (d) about 0.1 to about 3 weight % of a glidant; (e) about 0.1 to about 3 weight % of a lubricant; and (f) about 10 to about 25 weight % of a filler.
In a further embodiment, the pharmaceutical composition comprises: (a) 40 to 60 weight % of a solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; (b) 1 to 10 weight % of a disintegrant; (c) 15 to 25 weight % of an osmogen; (d) 0.1 to 3 weight % of a glidant; (e) 0.1 to 3 weight % of a lubricant; and (f) 10 to 25 weight % of a filler.
[0059] In certain embodiments, the osmogen is selected from NaCI and KCI, and mixtures thereof.
[0060] In certain embodiments, the lubricant is magnesium stearate.
[0061] In certain embodiments, the glidant is colloidal silicon dioxide.
[0062] In certain embodiments, the binder/ diluent is microcrystalline cellulose. In certain embodiments, the binder/ diluent acts as both a binder and a diluent.
[0063] In certain embodiments, the binder is microcrystalline cellulose.
[0064] In certain embodiments, the diluent is microcrystalline cellulose.
[0065] In certain embodiments, the filler is lactose.
[0066] In certain embodiments, the disintegrant is selected from crospovidone and sodium bicarbonate (NaHCO3), and mixtures thereof. In certain embodiments, the disintegrant is selected from crospovidone and sodium bicarbonate. In certain embodiments, the disintegrant is sodium bicarbonate. In certain embodiments, the disintegrant is crospovidone. [0067] In certain embodiments, the composition contains sodium bicarbonate. Λ/4-(4-([1,2,4]Triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine may slowly degrade, through hydrolysis or other means, to a carbamate impurity:
Sodium bicarbonate helps to slow the degradation to the carbamate impurity. Sodium bicarbonate also helps to provide consistent tablet disintegration when the tablets are exposed to different humidities.
[0068] Certain embodiments provide a pharmaceutical composition comprising: (a) Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazo-line-4,6-diamine; and (b) sodium bicarbonate.
[0069] Certain embodiments provide a pharmaceutical composition comprising: (a) about 1 to about 70 weight % of a solid dispersion of /V4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphe-nyl)-/V6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; and (b) about 0.1 to about 30 weight % sodium bicarbonate.
In a further embodiment, the pharmaceutical composition comprises: (a) 1 to 70 weight % of a solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; and (b) 0.1 to 30 weight % sodium bicarbonate.
[0070] Certain embodiments provide a pharmaceutical composition comprising: (a) about 1 to about 70 weight % of a solid dispersion of /V4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphe-nyl)-/V6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; (b) about 0.1 to about 30 weight % sodium bicarbonate; and (c) the remaining weight is other pharmaceutically acceptable excipients and carriers.
In a further embodiment, the pharmaceutical composition comprises: (a) 1 to 70 weight % of a solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; (b) 0.1 to 30 weight % sodium bicarbonate; and (c) the remaining weight is other pharmaceutically acceptable excipients and carriers.
[0071] Certain embodiments provide a pharmaceutical composition comprising: (a) about 25 to about 60 weight % of a solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphe-nyl)-/V6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; and (b) about 1 to about 15 weight % of sodium bicarbonate.
In a further embodiment, the pharmaceutical composition comprises: (a) 25 to 60 weight % of a solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; and (b) 1 to 15 weight % of sodium bicarbonate.
[0072] Certain embodiments provide a pharmaceutical composition comprising: (a) about 25 to about 60 weight % of a solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphe-nyl)-/V6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; (b) about 1 to about 15 weight % of sodium bicarbonate; and (c) the remaining weight is other pharmaceutically acceptable excipients and carriers.
In a further embodiment, the pharmaceutical composition comprises: (a) 25 to 60 weight % of a solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; (b) 1 to 15 weight % of sodium bicarbonate; and (c) the remaining weight is other pharmaceutically acceptable excipients and carriers.
[0073] Certain embodiments provide a pharmaceutical composition comprising: (a) about 40 to about 60 weight % of a solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphe-nyl)-/V6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; and (b) about 1 to about 15 weight % of sodium bicarbonate.
In a further embodiment, the pharmaceutical composition comprises: (a) 40 to 60 weight % of a solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; and (b) 1 to 15 weight % of sodium bicarbonate.
[0074] Certain embodiments provide a pharmaceutical composition comprising: (a) about 40 to about 60 weight % of a solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphe-nyl)-/V6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; (b) about 1 to about 15 weight % of sodium bicarbonate; (c) the remaining weight is other pharmaceutically acceptable excipients and carriers.
In a further embodiment, the pharmaceutical composition comprises: (a) 40 to 60 weight % of a solid dispersion of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; (b) 1 to 15 weight % of sodium bicarbonate; (c) the remaining weight is other pharmaceutically acceptable excipients and carriers.
[0075] The pharmaceutical composition preferably contains a therapeutically effective amount of Λ/4-(4-([1,2,4]triazo-lo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine. However, in some embodiments, each individual dose contains a portion of a therapeutically effective amount of Λ/4-(4-([1,2,4] triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, such that multiple doses of the composition may be required (for example, two or more tablets are required for a therapeutically effective amount). Thus, in this application when it states that the pharmaceutical composition contains a therapeutically effective amount it means that the composition may be one dose (for example, one tablet) or multiple doses (for example, two tablets). In certain embodiments, the pharmaceutical composition contains between 1 and 500 mg of Λ/4-(4-([1,2,4] triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine. [0076] In certain embodiments, the pharmaceutical composition contains between 25 and 400 mg of Λ/4-(4-([1,2,4] triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine. [0077] In certain embodiments, the pharmaceutical composition contains between 100 and 300 mg of Λ/4-(4-([1,2,4] triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine. [0078] The pharmaceutical compositions described herein may be administered by any convenient route appropriate to the condition to be treated. Suitable routes include oral, parenteral (including subcutaneous, intramuscular, intravenous, intraarterial, intradermal, intrathecal and epidural), transdermal, rectal, nasal, topical (including buccal and sublingual), ocular, vaginal, intraperitoneal, intrapulmonary and intranasal. If parenteral administration is desired, the compositions will be sterile and in a solution or suspension form suitable for injection or infusion.
[0079] The compounds may be administered in any convenient administrative form, e.g., tablets, powders, capsules, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc.
[0080] The pharmaceutical compositions described herein are typically administered orally. The pharmaceutical compositions described herein are typically administered as a tablet, caplet, hard or soft gelatin capsule, pill, granules or a suspension.
METHODS OF TREATMENT WITH COMPOUNDS OF THE INVENTION
[0081] Also described are methods of treating or preventing disease or condition by administering the pharmaceutical composition described herein. In one example, a human patient is treated with a pharmaceutical composition provided herein in an amount to inhibit ErbB2 activity. In one example, a human patient is treated with a pharmaceutical composition provided herein in an amount to detectably inhibit ErbB2 activity.
[0082] In another example, a method of treating a hyperproliferative disease in a mammal comprising administering the pharmaceutical composition provided herein, to the mammal is described.
[0083] In certain embodiments, the hyperproliferative disease is cancer.
[0084] In another example, a method of treating or preventing cancer in a mammal in need of such treatment is described, wherein the method comprises administering to said mammal a pharmaceutical composition provided herein. The cancer is selected from breast, ovary, cervix, prostate, testis, genitourinary tract, esophagus, larynx, glioblastoma, neuroblastoma, stomach, skin, keratoacanthoma, lung, epidermoid carcinoma, large cell carcinoma, NSCLC, small cell carcinoma, lung adenocarcinoma, bone, colon, adenoma, pancreas, adenocarcinoma, thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma, bladder carcinoma, liver carcinoma and biliary passages, kidney carcinoma, myeloid disorders, lymphoid disorders, hairy cells, buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx, small intestine, colon-rectum, large intestine, rectum, brain and central nervous system, Hodgkin’s and leukemia. Another embodiment provides the use of a pharmaceutical composition described herein, in the manufacture of a medicament for the treatment of cancer.
[0085] In another embodiment, the cancer is ErbB2 positive.
[0086] In another embodiment, the cancer is selected from breast, gastric, biliary, colorectal, lung, NSCLC, pancreatic, head and neck, ovarian, uterine and brain cancer.
[0087] In another embodiment, the cancer is selected from breast, gastric, biliary, colorectal, lung, NSCLC, pancreatic, head and neck, ovarian and uterine cancer.
[0088] In another embodiment, the cancer is selected from breast, gastric, colorectal, lung and ovarian cancer.
[0089] In another embodiment, the cancer is selected from breast, ovarian, gastric and uterine cancer.
[0090] In another embodiment, the cancer is selected from breast, gastric, colorectal, NSCLC and ovarian cancer.
[0091] In another embodiment, the cancer is selected from breast, lung, pancreatic, colorectal and head and neck cancers.
[0092] In another embodiment, the cancer is breast cancer.
[0093] In another embodiment, the cancer is gastric cancer.
[0094] In another embodiment, the cancer is biliary cancer.
[0095] In another embodiment, the cancer is colorectal cancer.
[0096] In another embodiment, the cancer is lung cancer.
[0097] In another embodiment, the cancer is NSCLC.
[0098] In another embodiment, the cancer is pancreatic cancer.
[0099] In another embodiment, the cancer is head and neck cancer.
[0100] In another embodiment, the cancer is ovarian cancer.
[0101] In another embodiment, the cancer is uterine cancer.
[0102] In another embodiment, the cancer is brain cancer.
[0103] In another example, a method of treating or preventing a disease or disorder modulated by ErbB2 is described, comprising administering to a mammal in need of such treatment an effective amount of a pharmaceutical composition provided herein. Examples of such diseases and disorders include, but are not limited to, cancer.
[0104] Another example describes the use of a pharmaceutical composition provided herein, in the manufacture of a medicament for the treatment of cancer.
[0105] Another embodiment provides the solid dispersions described herein for use in the treatment of disease. In a further embodiment, the disease is a hyperproliferative disease. In a further embodiment, the hyperproliferative disease is cancer.
[0106] Another embodiment provides the pharmaceutical compositions described herein for use in the treatment of disease. In a further embodiment, the disease is a hyperproliferative disease. In a further embodiment, the hyperproliferative disease is cancer.
EXAMPLES
[0107] For illustrative purposes, the following Examples are included. However, it is to be understood that these Examples do not limit the invention and are only meant to suggest a method of practicing the invention. Persons skilled in the art will recognize thatthe chemical reactions described may be readily adapted to prepare the compounds described herein, and alternative methods for preparing the compounds are deemed to be within the scope of this invention. For example, the synthesis of the compounds described herein may be successfully performed by modifications apparent to those skilled in the art, e.g., by appropriately protecting interfering groups, by utilizing other suitable reagents known in the art other than those described, and/or by making routine modifications of reaction conditions. Alternatively, other reactions disclosed herein or known in the art will be recognized as having applicability for preparing the compounds described herein. Persons skilled in the art will also recognize that the solid dispersions and compositions described may be readily adapted to prepare other dispersions and compositions, and alternative methods for preparing the dispersions and compositions, as well as alternative compositions are deemed to be within the scope of this invention.
Example 1
30% Solid Dispersion using PVP-VA
[0108] A solid dispersion was prepared containing 30 weight percent Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and PVP-VA using a Buchi B-290 mini spray drier. The solid dispersion was spray dried from a MeOH:THF (1:3) solvent system, a 5% spray solution concentration, an inlet temperature of 100°C at a flow rate of 22 mL/minute, drying gas flow rate of 35 m3/hour, nozzle pressure of 80 psig, nozzle gas flow of 0.66 m3/hour, and a 1.5 mm nozzle type. Secondary drying of the dispersion was done at 40°C under vacuum for about 16 hours. The spray drying yielded 19.6 g (87.7% yield) of the solid dispersion. Physicochemical analysis results are in Table 1. The XRPD scan is shown in Figure 1. Residual solvent analysis showed that the dispersion had less than 0.5% THF and no detectable MeOH.
[0109] Dissolution testing was performed at a pH of 6.5 in phosphate buffer. The solid dispersion was suspended in H2O and added directly to the buffer solution at 37°C. The dissolution profile was collected over a period of about 240 minutes. The results are in Figure 2. The Cmax and AUC for the total drug species (colloidal + free) was 63.46 μg/mL and 245.05 μg/mL*hr, respectively. The Cmax and AUC for the free drug species was 52.50 μg/mL and 204.12 μg/mL*hr, respectively.
Example 2 30% Solid Dispersion using Eudragit [0110] A solid dispersion was prepared containing 30 weight percent Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and Eudragit L100 using a Buchi B-290 mini spray drier. The solid dispersion was spray dried from a MeOH:THF (1:3) solvent system, a 5% spray solution concentration, an inlet temperature of 100°C at a flow rate of 22 mL/minute, drying gas flow rate of 35 m3/hour, nozzle pressure of 80 psig, nozzle gas flow of 0.66 m3/hour, and a 1.5 mm nozzle type. Secondary drying of the dispersion was done at 40°C under vacuum for about 16 hours. The spray drying yielded 18.6 g (82.7% yield) of the solid dispersion. Physicochemical analysis results are in Table 1. The XRPD scan is shown in Figure 1. Residual solvent analysis showed that the dispersion had about 4.5% THF and no detectable MeOH.
[0111] Dissolution testing was performed at a pH of 6.5 in phosphate buffer. The solid dispersion was suspended in H2O and added directly to the buffer solution at 37°C. The dissolution profile was collected over a period of about 240 minutes. The results are in Figure 3. The Cmax and AUC for the total drug species (colloidal + free) was 22.70 μg/mL and 71.06 μg/mL*hr, respectively. The Cmax and AUC for the free drug species was 9.26 μg/mL and 35.49 μg/mL*hr, respectively.
Example 3
30% Solid Dispersion using HPMCP
[0112] A solid dispersion was prepared containing 30 weight percent Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and HPMCP H-55 using a Buchi B-290 mini spray drier. The solid dispersion was spray dried from a MeOH:THF (1:3) solvent system, a 5% spray solution concentration, an inlet temperature of 100°C at a flow rate of 22 mL/minute, drying gas flow rate of 35 m3/hour, nozzle pressure of 80 psig, nozzle gas flow of 0.66 m3/hour, and a 1.5 mm nozzle type. Secondary drying of the dispersion was done at 40°C under vacuum for about 16 hours. The spray drying yielded 20.3 g (90.3% yield) of the solid dispersion. Physicochemical analysis results are in Table 1. The XRPD scan is shown in Figure 1. Residual solvent analysis showed that the dispersion had less than 0.5% THF and no detectable MeOH.
[0113] Dissolution testing was performed at a pH of 6.5 in phosphate buffer. The solid dispersion was suspended in H2O and added directly to the buffer solution at 37°C. The dissolution profile was collected over a period of about 240 minutes. The results are in Figure 4. The Cmax and AUC for the total drug species (colloidal + free) was 25.00 μg/mL and 96.66 μg/mL*hr, respectively. The Cmax and AUC for the free drug species was 16.15 μg/mL and 56.81 μg/mL*hr, respectively.
Example 4
30% Solid Dispersion using CAP
[0114] A solid dispersion was prepared containing 30 weight percent Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and CAP using a Buchi B-290 mini spray drier. The solid dispersion was spray dried from a MeOH:THF (1:3) solvent system, a 5% spray solution concentration, an inlet temperature of 100°C at a flow rate of 22 mL/minute, drying gas flow rate of 35 m3/hour, nozzle pressure of 80 psig, nozzle gas flow of 0.66 m3/hour, and a 1.5 mm nozzle type. Secondary drying of the dispersion was done at 40°C under vacuum for about 16 hours. The spray drying yielded 20.0 g (90.4% yield) of the solid dispersion. Physicochemical analysis results are in Table 1. The XRPD scan is shown in Figure 1. Residual solvent analysis showed that the dispersion had less than 0.5% THF and no detectable MeOH.
[0115] Dissolution testing was performed at a pH of 6.5 in phosphate buffer. The solid dispersion was suspended in H2O and added directly to the buffer solution at 37°C. The dissolution profile was collected over a period of about 240 minutes. The results are in Figure 5. The Cmax and AUC for the total drug species (colloidal + free) was 11.62 μg/mL and 36.69 μg/mL*hr, respectively. The Cmax and AUC for the free drug species was 5.64 μg/mL and 20.58 μg/mL*hr, respectively.
Example 5
30% Solid Dispersion using HPMCAS
[0116] A solid dispersion was prepared containing 30 weight percent Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and HPMCAS Grade M using a Buchi B-290 mini spray drier. The solid dispersion was spray dried from a MeOH:THF (1:3) solvent system, a 5% spray solution concentration, an inlet temperature of 80°C at a flow rate of 35 mL/minute, drying gas flow rate of 40 m3/hour, nozzle pressure of 80 psig, nozzle gas flow of 0.66 m3/hour, and a 1.5 mm nozzle type. Secondary drying of the dispersion was done at40°C under vacuum for about 16 hours. The spray drying yielded 163.19 mg (48.3% yield) of the solid dispersion. Physicochemical analysis results are in Table 1. The XRPD scan is shown in Figure 1. Residual solvent analysis showed that the dispersion had less than 0.5% THF and no detectable MeOH.
[0117] Dissolution testing was performed at a pH of 6.5 in phosphate buffer. The solid dispersion was suspended in H2O and added directly to the buffer solution at 37°C. The dissolution profile was collected over a period of about 240 minutes. The results are in Figure 6. The Cmax and AUC for the total drug species (colloidal + free) was 19.04 μg/mL and 68.09 μg/mL*hr, respectively. The Cmax and AUC for the free drug species was 13.50 μg/mL and 51.74 μg/mL*hr, respectively.
Table 1
Example Polymer API: HPLC Tg TGA % Hygroscopicity
Polymer (area%) (°C) wt loss THF (% wt change _(%) (w/w) at 80% RH) RE I 99.39 4.9 10,, 1 P\P-\.\ 3:7 99.45 IP 2.3 0.5 14.4 2 Kudnigit 3:7 9S.63 116 5.9 4.5 7.5 3 IIPMCP 3:7 97.30 149 IP ().3 7.5 11-55
4 CAP 3P 95.45 179 1.9 0.5 “S
5 HPMCAS 3:7_113 NA NA_NA
Example 6
60% Solid Dispersion using PVP-VA
[0118] A solid dispersion was prepared containing 60 weight percent Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and PVP-VA using a Buchi B-290 mini spray drier. The solid dispersion was spray dried from a MeOH:THF (1:3) solvent system, a 5% spray solution concentration, an inlet temperature of 80°C at a flow rate of 35 mL/minute, drying gas flow rate of 40 m3/hour, nozzle pressure of 80 psig, nozzle gas flow of 0.66 m3/hour, and a 1.5 mm nozzle type. Secondary drying of the dispersion was done at 40°C under vacuum for about 16 hours. The spray drying yielded 135.0 mg (88.2% yield) of the solid dispersion. The XRPD scan is shown in Figure 7.
[0119] Dissolution testing was performed at a pH of 6.5 in phosphate buffer. The solid dispersion was suspended in H2O and added directly to the buffer solution at 37°C. The dissolution profile was collected over a period of about 240 minutes. The results are in Figure 8. The Cmax and AUC for the total drug species (colloidal + free) was 34.80 μg/mL and 133.76 μg/mL*hr, respectively. The Cmax and AUC for the free drug species was 21.88 μg/mL and 84.43 μg/mL*hr, respectively.
Example 7 60% Solid Dispersion using Eudragit [0120] A solid dispersion was prepared containing 60 weight percent Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and Eudragit L100 using a Buchi B-290 mini spray drier. The solid dispersion was spray dried from a MeOH:THF (1:3) solvent system, a 5% spray solution concentration, an inlet temperature of 80°C at a flow rate of 35 mL/minute, drying gas flow rate of 40 m3/hour, nozzle pressure of 80 psig, nozzle gas flow of 0.66 m3/hour, and a 1.5 mm nozzle type. Secondary drying of the dispersion was done at 40°C under vacuum for about 16 hours. The spray drying yielded 88.1 mg (52.4% yield) of the solid dispersion. The XRPD scan is shown in Figure 7.
[0121] Dissolution testing was performed at a pH of 6.5 in phosphate buffer. The solid dispersion was suspended in H2O and added directly to the buffer solution at 37°C. The dissolution profile was collected over a period of about 240 minutes. The results are in Figure 9. The Cmax and AUC for the total drug species (colloidal + free) was 26.82 μg/mL and 84.49 μg/mL*hr, respectively. The Cmax and AUC for the free drug species was 9.85 μg/mL and 34.89 μg/mL*hr, respectively.
Example 8
60% Solid Dispersion using HPMCP
[0122] A solid dispersion was prepared containing 60 weight percent Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and HPMCP H-55 using a Buchi B-290 mini spray drier. The solid dispersion was spray dried from a MeOH:THF (1:3) solvent system, a 5% spray solution concentration, an inlet temperature of 80°C at a flow rate of 35 mL/minute, drying gas flow rate of 40 m3/hour, nozzle pressure of 80 psig, nozzle gas flow of 0.66 m3/hour, and a 1.5 mm nozzle type. Secondary drying of the dispersion was done at 40°C under vacuum for about 16 hours. The spray drying yielded 98.0 mg (58.0% yield) of the solid dispersion. The XRPD scan is shown in Figure 7.
[0123] Dissolution testing was performed at a pH of 6.5 in phosphate buffer. The solid dispersion was suspended in H2O and added directly to the buffer solution at 37°C. The dissolution profile was collected over a period of about 240 minutes. The results are in Figure 10. The Cmax and AUC for the total drug species (colloidal + free) was 32.21 μg/mL and 38.28 μg/mL*hr, respectively. The Cmax and AUC for the free drug species was 9.96 μg/mL and 38.28 μg/mL*hr, respectively.
Example 9
60% Solid Dispersion using CAP
[0124] A solid dispersion was prepared containing 60 weight percent Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and CAP using a Buchi B-290 mini spray drier. The solid dispersion was spray dried from a MeOH:THF (1:3) solvent system, a 5% spray solution concentration, an inlet temperature of 80°C at a flow rate of 35 mL/minute, drying gas flow rate of 40 m3/hour, nozzle pressure of 80 psig, nozzle gas flow of 0.66 m3/hour, and a 1.5 mm nozzle type. Secondary drying of the dispersion was done at 40°C under vacuum for about 16 hours. The spray drying yielded 74.9 mg (44.6% yield) of the solid dispersion. The XRPD scan is shown in Figure 7.
[0125] Dissolution testing was performed at a pH of 6.5 in phosphate buffer. The solid dispersion was suspended in H2O and added directly to the buffer solution at 37°C. The dissolution profile was collected over a period of about 240 minutes. The results are in Figure 11. The Cmax and AUC for the total drug species (colloidal + free) was 51.98 μg/mL and 144.91 μg/mL*hr, respectively. The Cmax and AUC for the free drug species was 15.07 μg/mL and 59.69 μg/mL*hr, respectively.
Example 10
60% Solid Dispersion using HPMCAS
[0126] A solid dispersion was prepared containing 60 weight percent Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and HPMCAS Grade M using a Buchi B-290 mini spray drier. The solid dispersion was spray dried from a MeOH:THF (1:3) solvent system, a 5% spray solution concentration, an inlet temperature of 80°C at a flow rate of 35 mL/minute, drying gas flow rate of 40 m3/hour, nozzle pressure of 80 psig, nozzle gas flow of 0.66 m3/hour, and a 1.5 mm nozzle type. Secondary drying of the dispersion was done at 40°C under vacuum for about 16 hours. The spray drying yielded 113.3 mg (67.2% yield) of the solid dispersion. The XRPD scan is shown in Figure 7.
[0127] Dissolution testing was performed at a pH of 6.5 in phosphate buffer. The solid dispersion was suspended in H2O and added directly to the buffer solution at 37°C. The dissolution profile was collected over a period of about 240 minutes. The results are in Figure 12. The Cmax and AUC for the total drug species (colloidal + free) was 26.45 μg/mL and 96.21 μg/mL*hr, respectively. The Cmax and AUC for the free drug species was 10.96 μg/mL and 42.83 μg/mL*hr, respectively.
Example 11
50% Solid Dispersion using PVP-PA
[0128] A solid dispersion was prepared containing 50 weight percent Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and PVP-VA using a Buchi B-290 mini spray drier. The solid dispersion was spray dried from a MeOH:THF (1:3) solvent system, a 3.9% spray solution concentration, an inlet temperature of 100°C at a flow rate of 30 mL/minute, drying gas flow rate of 40 m3/hour, nozzle pressure of 80 psig, nozzle gas flow of 0.66 m3/hour, and a 1.5 mm nozzle type. Secondary drying of the dispersion was done at 50°C under vacuum for about 72 hours. The spray drying yielded 28.7 g (72.7% yield) of the solid dispersion.
Example 12 (reference example) Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine freebase hemi-ethanolate [0129] Step 1: (E)-/V’-(2-Cyano-4-(3-(1-hydroxy-2-methylpropan-2-yl)thioureido) phenyl)-/V,/V-dimethylformimidamide was coupled with 4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylaniline in isopropyl acetate:acetic acid (65:35 v/v) at 45°C to yield 1-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)amino)quinazolin-6-yl)-3-(1-hydroxy -2-methylpropan-2-yl)thiourea (91%).
[0130] Step 2: 1-(4-((4-([1,2,4]Triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl) amino)quinazolin-6-yl)-3-(1-hydroxy-2-methylpropan-2-yl)thiourea was agitated in tetrahydrofuran under basic conditions (2.5N NaOH), followed by the addition of p-toluenesulfonyl chloride. Water was charged to yield Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphe-nyl)-/V6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine (96%) as a mixture of polymorphs (generally a mixture containing one or more of Form C, Form G hemi-THF, Form G mono-THF, Form M or Form P).
[0131] Step 3: Λ/4-(4-([1,2,4]Triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diaminefrom Step 2 was triturated in ethanol at greater than 65°C to provide Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol (89%).
[0132] The crystalline hemi-ethanolate (Form B Ethanol) XRPD scans are shown in Figures 1 and 7.
[0133] Dissolution testing was performed at a pH of 6.5 in phosphate buffer. The crystals (particles) were suspended in H2O and added directly to the buffer solution at 37°C. The dissolution profile was collected over a period of about 240 minutes. The Cmax and AUC for the free drug species was 0.44 μg/mL and 5.49 μg/mL*hr, respectively.
Example 13
Pharmaceutical Composition 1 [0134] Tablets containing the solid dispersions of any of Examples 1 to 11 may be prepared in a conventional manner comprising:
[0135] In one preparation, tablets were made using OPADRY II 85F92727 at 3% by weight as a tablet coating. The tablets contained 150 mg of API.
Example 14
Pharmaceutical Composition 2 [0136] Tablets containing the solid dispersions of any of Examples 1 to 11 may be prepared in a conventional manner comprising:
[0137] In one preparation, tablets were made using OPADRY II 85F92727 at 3% by weight as a tablet coating. The tablets contained 150 mg of API.
Example 15
Pharmaceutical Composition 3 [0138] Tablets containing the solid dispersions of any of Examples 1 to 11 may be prepared in a conventional manner comprising:
[0139] In one preparation, tablets were made using OPADRY II 85F92727 at 3% by weight as a tablet coating. The tablets contained 150 mg of API.
Example 16
Referential Pharmaceutical Composition - Powder-in-Capsule [0140] A PIC composition was prepared containing 25 mg or 100 mg of Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol -2-yl)quinazoline-4,6-diamine as prepared in Example 12. The PIC composition was prepared in size 00 white opaque hard gelatin capsules.
[0141] A dissolution test comparison was performed comparing the crystalline hemi-ethanolate PIC composition of Example 16 and the 50% PVP-VA solid dispersion (Example 11) tablet of Example 13 in 900 mL of 10 mM citrate buffer at 37°C and a pH of 4.5, using USP Apparatus II at 75 rpm. The results are shown in Figure 13.
Example 17
Stability Screen [0142] A stability screen of the spray dried dispersions was completed at 40°C, 75% relative humidity under open conditions, in glass vials, over a period of 8 days. Results are shown in TABLE 2. TABLE 2
[0143] The main dégradant observed was the carbamate impurity, likely due to the acidic nature of some of these polymers. XRPD analysis over the course of the study showed no evidence of crystallization for any solid dispersion of Examples 1-4.
Example 18
In vivo Pharmacokinetics in Beagles [0144] The solid dispersion of Example 1 was tested against a crystalline, micronized suspension formulation (d(v, 0.9) = 3.0μΐτι) of Example 12 under normal fasted conditions, as well as with pretreatment using pentagastrin orfamotidine. The solid dispersion of Example 1 was prepared as a suspension in water and administered orally. The micronized suspension of Example 12 was prepared as a suspension with SyrSpend® SF Dry reconstituted with water and administered orally. To reduce variability, beagles were crossed over from pentagastrin to famotidine after a 5 day washout period. Pentagastrin is a pH modifier to modify gastric pH to about 2 to 3, and famotidine is a pH modifier to modify gastric pH to about 5 to 7.5 (Zhou, Rong, et al. "pH-Dependent Dissolution in Vitro and Absorption in Vivo of Weakly Basic Drugs: Development of a Canine Model." Pharm. Res. Vol. 22, No. 2 (Feb. 2005): pp. 188-192). There were four beagles per group. Group A received pentagastrin pretreatment, the micronized suspension of Example 12, followed by a 5 day washout period, then famotidine pretreatment, and finally the micronized suspension of Example 12. Group B received pentagastrin pretreatment, the solid dispersion of Example 1, followed by a 5 day washout period, then famotidine pretreatment, and finally the solid dispersion of Example 1. Group C received the micronized suspension of Example 12, followed by a 5 day washout period, and finally the solid dispersion of Example 1. Results are shown in TABLE 3.
TABLE 3
[0145] It will be understood that the enumerated embodiments are not intended to limit the invention to those embodiments. On the contrary, the invention is intended to cover all alternatives, modifications and equivalents, which may be included within the scope of the present invention as defined by the claims. Thus, the foregoing description is considered as illustrative only of the invention as claimed.
[0146] The words "comprise," "comprising," "include," "including," and "includes" when used in this specification and in the following claims are intended to specify the presence of stated features, integers, components, or steps, but they do not preclude the presence or addition of one or more other features, integers, components, steps, or groups thereof.
Claims 1. A solid dispersion comprising Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-di-hydrooxazol-2-yl)quinazoline-4,6-diamine and a dispersion polymer. 2. The solid dispersion of Claim 1, comprising amorphous /V4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphe-nyl)-/V6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine. 3. The solid dispersion of Claims 1 or2, wherein the dispersion polymer is selected from vinyl polymers and copolymers, PVP-VA, polyvinyl alcohols, polyvinyl alcohol polyvinyl acetate copolymers, PVP, acrylate and methacrylate copolymers, methylacrylic acid methyl methacrylate copolymer, polyethylene polyvinyl alcohol copolymers, polyoxyeth-ylene-polyoxypropylene block copolymers, graft copolymer comprised of polyethylene glycol, polyvinyl caprolactam and polyvinyl acetate, cellulosic polymers, such as hydroxypropyl methyl cellulose acetate, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl cellulose, hydroxyethyl cellulose acetate, and hydroxyethyl ethyl cellulose, hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, carboxymethylethyl cellulose, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropyl methyl cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methyl cellulose acetate trimellitate, and carboxymethylcellulose acetate butyrate. 4. The solid dispersion of any one of Claims 1 to 3, wherein the dispersion polymer is methylacrylic acid / methyl methacrylate copolymer. 5. The solid dispersion of any one of Claims 1 to 3, wherein the dispersion polymer is hydroxypropylmethyl cellulose phthalate. 6. The solid dispersion of any one of Claims 1 to 3, wherein the dispersion polymer is cellulose acetate phthalate. 7. The solid dispersion of any one of Claims 1 to 3, wherein the dispersion polymer is selected from vinylpyrrolidine / vinylacetate copolymer and hydroxypropyl methyl cellulose, or mixtures thereof. 8. The solid dispersion of any one of Claims 1 to 3, wherein the dispersion polymer is vinylpyrrolidine / vinylacetate copolymer. 9. The solid dispersion of any one of Claims 1 to 3, wherein the dispersion polymer is hydroxypropyl methyl cellulose. 10. The solid dispersion of any one of Claims 1 to 9, wherein the Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methyl- phenyl)-/V6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is present in an amount of from about 0.1 % to about 50% by weight relative to the dispersion polymer. 11. The solid dispersion of any one of Claims 1 to 10, wherein at least 80% of the Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is in amorphous form. 12. The solid dispersion of Claim 11, wherein at least 95% of the Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methyl-phenyl)-/V6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is in amorphous form. 13. A pharmaceutical composition comprising a solid dispersion according to anyone of Claims 1 to 12 and one or more pharmaceutically acceptable excipients. 14. The pharmaceutical composition of Claim 13, wherein the composition is a tablet. 15. The pharmaceutical composition of Claim 13 comprising: (a) about 1 to about 70 weight % of the solid dispersion of any one of Claims 1 to 12; (b) about 0.1 to 20 weight % of a disintegrant; (c) about 0.1 to 25 weight % of an osmogen; (d) about 0.1 to 10 weight % of a glidant; (e) about 0.1 to 10 weight % of a lubricant; and (f) about 0.1 to 25 weight % of a binder. 16. A pharmaceutical composition of Claim 13 comprising: (a) Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-/\/6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; and (b) sodium bicarbonate. 17. The pharmaceutical composition of Claim 16 comprising: (a) about 1 to about 70 weight % of the solid dispersion of any one of Claims 1 to 12; and (b) about 0.1 to about 30 weight % sodium bicarbonate. 18. The pharmaceutical composition of any one of Claims 13 to 17, wherein the solid dispersion is about 25 to about 60 weight %. 19. The solid dispersion of any one of Claims 1 to 18 for use in the treatment of a disease. 20. The solid dispersion for use of Claim 19, wherein the disease is cancer. 21. The solid dispersion for use of Claim 20, wherein the cancer is selected from breast, gastric, biliary, colorectal, lung, non-small cell lung cancer, pancreatic, head and neck, ovarian, uterine and brain cancer. 22. The solid dispersion for use of Claims 20 or 21, wherein the cancer is ErbB2 positive.
Patentansprüche 1. Feststoffdispersion, umfassend N4-(4-([1,2,4]Triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)chinazolin-4,6-diamin und ein Dispersionspolymer. 2. Feststoffdispersion nach Anspruch 1, umfassend amorphes N4-(4-([1,2,4]Triazolo[1,5-a]pyridin-7-yloxy)-3-methyl-phenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)chinazolin-4,6-diamin. 3. Feststoffdispersion nach Anspruch 1 oder 2, wobei das Dispersionspolymer ausgewählt ist aus Vinylpolymeren und Copolymeren, PVP-VA, Polyvinylalkoholen, Polyvinylalkohol-Polyvinylacetat-Copolymeren, PVP, Acrylat- und Me-thacrylatcopolymeren, Methylacrylsäure-Methylmethacrylat-Copolymer, Polyethylen-Polyvinylalkohol-Copolyme- ren, Polyoxyethylen-Polyoxypropylen-Blockcopolymeren, Pfropfcopolymer, bestehend aus Polyethylenglycol, Polyvinylcaprolactam und Polyvinylacetat, Cellulosepolymeren, wie etwa Hydroxypropylmethylcelluloseacetat, Hydro-xypropylmethylcellulose, Hydroxypropylcellulose, Methylcellulose, Hydroxyethylmethylcellulose, Hydroxyethylcel-lulose, Hydroxyethylcelluloseacetat und Hydroxyethylethylcellulose, Hydroxypropylmethylcelluloseacetatsuccinat, Hydroxypropylmethylcellulosephthalat, Carboxymethylethylcellulose, Celluloseacetatphthalat, Celluloseacetatsuc-cinat, Hydroxypropylmethylcelluloseacetatphthalat, Celluloseacetattrimellitat, Hydroxypropylmethylcelluloseacetat-trimellitat und Carboxymethylcelluloseacetatbutyrat. 4. Feststoffdispersion nach einem der Ansprüche 1 bis 3, wobei das Dispersionspolymer Methylacrylsäure/Methylme-thacrylat-Copolymer ist. 5. Feststoffdispersion nach einem der Ansprüche 1 bis 3, wobei das Dispersionspolymer Hydroxypropylmethylcellu-losephthalat ist. 6. Feststoffdispersion nach einem der Ansprüche 1 bis 3, wobei das Dispersionspolymer Celluloseacetatphthalat ist. 7. Feststoffdispersion nach einem der Ansprüche 1 bis 3, wobei das Dispersionspolymer ausgewählt ist aus Vinylpyr-rolidinA/inylacetat-Copolymer und Hydroxypropylmethylcellulose oder Gemischen daraus. 8. Feststoffdispersion nach einem der Ansprüche 1 bis 3, wobei das Dispersionspolymer VinylpyrrolidinA/inylacetat-Copolymer ist. 9. Feststoffdispersion nach einem der Ansprüche 1 bis 3, wobei das Dispersionspolymer Hydroxypropylmethylcellulose ist. 10. Feststoffdispersion nach einem der Ansprüche 1 bis 9, wobei das N4-(4-([1,2,4]Triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)chinazolin-4,6-diamin in einer Menge vorliegt, die etwa 0,1 Gew.-% bis etwa 50 Gew.-% mit Bezug auf das Dispersionspolymer beträgt. 11. Feststoffdispersion nach einem der Ansprüche 1 bis 10, wobei wenigstens 80 % des N4-(4-([1,2,4]Triazolo[1,5-a] pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)chinazolin-4,6-diamins in einer amorphen Form vorliegt. 12. Feststoffdispersion nach Anspruch 11, wobei wenigstens 95 % des N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)chinazolin-4,6-diamins in einer amorphen Form vorliegt. 13. Pharmazeutische Zusammensetzung, umfassend eine Feststoffdispersion nach einem der Ansprüche 1 bis 12 und einen oder mehrere pharmazeutisch unbedenkliche Hilfsstoffe. 14. Pharmazeutische Zusammensetzung nach Anspruch 13, wobei die Zusammensetzung eine Tablette ist. 15. Pharmazeutische Zusammensetzung nach Anspruch 13, Folgendes umfassend: (a) etwa 1 bis etwa 70 Gew.-% der Feststoffdispersion nach einem der Ansprüche 1 bis 12; (b) etwa 0,1 bis 20 Gew.-% eines Sprengmittels; (c) etwa 0,1 bis 25 Gew.-% eines Osmogens; (d) etwa 0,1 bis 10 Gew.-% eines Gleitstoffs; (e) etwa 0,1 bis 10 Gew.-% eines Schmierstoffs; und (f) etwa 0,1 bis 25 Gew.-% eines Bindemittels. 16. Pharmazeutische Zusammensetzung nach Anspruch 13, Folgendes umfassend: (a) N4-(4-([1,2,4]Triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)chi-nazolin-4,6-diamin; und (b) Natriumbicarbonat. 17. Pharmazeutische Zusammensetzung nach Anspruch 16, Folgendes umfassend: (a) etwa 1 bis etwa 70 Gew.-% der Feststoffdispersion nach einem der Ansprüche 1 bis 12; und (b) etwa 0,1 bis etwa 30 Gew.-% Natriumbicarbonat. 18. Pharmazeutische Zusammensetzung nach einem der Ansprüche 13 bis 17, wobei die Feststoffdispersion etwa 25 bis 60 Gew.-% ausmacht. 19. Feststoffdispersion nach einem der Ansprüche 1 bis 18 für die Verwendung beim Behandeln einer Erkrankung. 20. Feststoffdispersion für die Verwendung nach Anspruch 19, wobei die Erkrankung Krebs ist. 21. Feststoffdispersion für die Verwendung nach Anspruch 20, wobei der Krebs ausgewählt ist aus Brust-, Magen-, Gallengang-, Kolorektal-, Lungen-, nicht kleinzelligem Lungenkrebs, Pankreas-, Kopf- und Hals-, Eierstock, Gebärmutter- und Hirnkrebs. 22. Feststoffdispersion für die Verwendung nach Anspruch 20 oder 21, wobei der Krebs ErbB2-positiv ist.
Revendications 1. Dispersion solide comprenant de la Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-méthylphényl)-/\/6-(4,4-diméthyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine et un polymère de dispersion. 2. Dispersion solide selon la revendication 1, comprenant de la N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-méthyl-phényl)-/V6-(4,4-diméthyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine amorphe. 3. Dispersion solide selon la revendication 1 ou 2, dans laquelle le polymère de dispersion est choisi parmi des polymères et des copolymères de vinyle, du PVP-VA, des alcools polyvinyliques, des copolymères d’alcool polyvi-nylique acétate de polyvinyle, du PVP, des copolymères d’acrylate et de méthacrylate, des copolymères d’acide méthylacrylique méthacrylate de méthyle, des copolymères de polyéthylène alcool polyvinylique, des copolymères séquencés de polyoxyéthylène-polyoxypropylène, des copolymères greffés constitués de polyéthylèneglycol, de polyvinyl Caprolactame et d’acétate de polyvinyle, des polymères cellulosiques tels que l’acétate d’hydroxypropyl méthyl cellulose, l’hydroxypropyl méthyl cellulose, l’hydroxypropyl cellulose, la méthyl cellulose, l’hydroxyéthyl mé-thyl cellulose, l’hydroxyéthyl cellulose, l’acétate d’hydroxyéthyl cellulose et l’hydroxyéthyl éthyl cellulose, l’acétate succinate d’hydroxypropyl méthyl cellulose, le phtalate d’hydroxypropyl méthyl cellulose, la carboxyméthyl éthyl cellulose, l’acétate phtalate de cellulose, l’acétate succinate de cellulose, l’acétate phtalate d’hydroxypropyl méthyl cellulose, l’acétate trime11itate de cellulose, l’acétate trimellitate d’hydroxypropyl méthyl cellulose et l’acétate butyrate de carboxyméthyl cellulose. 4. Dispersion solide selon l’une quelconque des revendications 1 à 3, dans laquelle le polymère de dispersion est un copolymère d’acide méthylacrylique / méthacrylate de méthyle. 5. Dispersion solide selon l’une quelconque des revendications 1 à 3, dans laquelle le polymère de dispersion est le phtalate d’hydroxypropyl méthyl cellulose. 6. Dispersion solide selon l’une quelconque des revendications 1 à 3, dans laquelle le polymère de dispersion est l’acétate phtalate de cellulose. 7. Dispersion solide selon l’une quelconque des revendications 1 à 3, dans laquelle le polymère de dispersion est choisi parmi un copolymère de vinylpyrrolidine / acétate de vinyle et l’hydroxypropyl méthyl cellulose, ou leurs mélanges. 8. Dispersion solide selon l’une quelconque des revendications 1 à 3, dans laquelle le polymère de dispersion est un copolymère de vinylpyrrolidine / acétate de vinyle. 9. Dispersion solide selon l’une quelconque des revendications 1 à 3, dans laquelle le polymère de dispersion est l’hydroxypropyl méthyl cellulose. 10. Dispersion solide selon l’une quelconque des revendications 1 à 9, dans laquelle la Λ/4-(4-([1,2,4]triazolo[1,5-a] pyridin-7-yloxy)-3-méthylphényl)-/V6-(4,4-diméthyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine est présente en une quantité d’environ 0,1 % à environ 50 % en poids par rapport au polymère de dispersion. 11. Dispersion solide selon l’une quelconque des revendications 1 à 10, dans laquelle au moins 80 % de la Λ/4-(4-([1,2,4] triazolo[1,5-a]pyridin-7-yloxy)-3-méthylphényl)-/\/6-(4,4-diméthyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine sont présents sous une forme amorphe. 12. Dispersion solide selon la revendication 11, dans laquelle au moins 95 % de la N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-méthylphényl)-/\/6-(4,4-diméthyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine sont présents sous une forme amorphe. 13. Composition pharmaceutique comprenant une dispersion solide selon l’une quelconque des revendications 1 à 12 et un ou plusieurs excipients pharmaceutiquement acceptables. 14. Composition pharmaceutique selon la revendication 13, dans laquelle la composition est un comprimé. 15. Composition pharmaceutique selon la revendication 13, comprenant : (a) d’environ 1 à environ 70 % en poids de la dispersion solide selon l’une quelconque des revendications 1 à 12 ; (b) d’environ 0,1 à 20 % en poids d’un délitant ; (c) d’environ 0,1 à 25 % en poids d’un osmogène ; (d) d’environ 0,1 à 10 % en poids d’un agent de glissement ; (e) d’environ 0,1 à 10 % en poids d’un lubrifiant ; et (f) d’environ 0,1 à 25 % en poids d’un liant. 16. Composition pharmaceutique selon la revendication 13, comprenant : (a) de la Λ/4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-méthylphényl)-/\/6-(4,4-diméthyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine ; et (b) du bicarbonate de sodium. 17. Composition pharmaceutique selon la revendication 16, comprenant : (a) d’environ 1 à environ 70 % en poids de la dispersion solide selon l’une quelconque des revendications 1 à 12 ; et (b) d’environ 0,1 à environ 30 % en poids de bicarbonate de sodium. 18. Composition pharmaceutique selon l’une quelconque des revendications 13 à 17, dans laquelle la dispersion solide représente d’environ 25 à environ 60 % en poids. 19. Composition pharmaceutique selon l’une quelconque des revendications 1 à 18, pour son utilisation dans le traitement d’une maladie. 20. Dispersion solide pour son utilisation selon la revendication 19, dans laquelle la maladie est un cancer. 21. Dispersion solide pour son utilisation selon la revendication 20, dans laquelle le cancer est choisi parmi un cancer du sein, un cancer gastrique, un cancer biliaire, un cancer colorectal, un cancer du poumon, un cancer du poumon non à petites cellules, un cancer pancréatique, un cancer de la tête et du cou, un cancer des ovaires, un cancer de l’utérus et un cancer du cerveau. 22. Dispersion solide pour son utilisation selon la revendication 20 ou 21, dans laquelle le cancer est ErbB2 positif.
REFERENCES CITED IN THE DESCRIPTION
This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.
Patent documents cited in the description • WO 2007059257 A [0002]
Non-patent literature cited in the description • KOCH ; KEVIN. ARRY-380: A Selective, Oral HER2 · ANSEL ; HOWARD C. et al. Ansel’s Pharmaceutical
InhibitorfortheTreatment of SolidTumors. American Dosage Forms and Drug Delivery Systems. Lippin-
Association of Cancer Research 102nd Annual Meet- cott, Williams & Wilkins, 2004 [0051] ing, 03 April 2011 [0002] · GENNARO ; ALFONSO R. et al. Remington: The • Solid dispersions as strategy to improve oral bioa- Science and Practice of Pharmacy. Williams & vailability of poor water soluble drugs. VASCONCE- Wilkins, 2000 [0051] LOS et al. Drug Discovery Today. Elsevier, 30 Oc- · ROWE ; RAYMONDC. Handbookof Pharmaceutical tober2007, vol. 12, 1068-1075 [0004] Excipients. Pharmaceutical Press, 2005 [0051] • Perry’s Chemical Engineers’ Handbook. Me- · ZHOU ; RONG et al. pH-Dependent Dissolution in
Graw-Hill, 2007 [0023] Vitro and Absorption in Vivo of Weakly Basic Drugs:
Development of a Canine Model. Pharm. Res., February 2005, vol. 22 (2), 188-192 [0144]

Claims (7)

  1. S záisada i ;ο ί :>;,<· e ypsiere k i. Sziked diszperzió: aareiy piriaisrisz V·?· i d· ; : ;.d Víki-z<?k-H :<7 !· ijî: :5< : i î ··;. 5 · <; ; hîîJî'· >ίΐ:<;>χ·Λ>: · '?' i ; }k i ;':Ss.Z<d ! : >· '4 6··<1 ii-ru !-7=. ÓS diXZpS; 'ZiéS pöÜaWk i: Az i. ígérsvp;só szeriüd sziláid diszpe!'pie, afeely ..eîsioiaz ;ii‘îï«rf Ad'-i4kri,g,4}!ri3zok>ii;.5:· •;ÍpiS:öi:;.7bkiS i zó-eeeiideib: :· SÓÓ :.4-d:::AX?i'·< . '· όι0ίΡθ.:ΟχΖΖ:.0- b i i A leszoki':- bő d izei :3:. a, Az k vagy ók igéayporg ><?<.5 ΐ;·>:;·> szilárd diszperzab bed s íiiszgeyziés pebriîee a kóvsrkezök közök välaszieg: virrii peibeerek ás k‘>p<>H«?í5rv.k.; kVP-VAs perii vodkalkehor.iok, ppiri V;ód--aiksíóö;bpoi:i(viidi--aeeiár} kùpoH merek, PVP. abrPa· ás seeiakrilpi kepsbissrek, i'iíeiiíiikfíkiav-'iTieííí'SAfákrááí kopokroei, peiiebier!-p«;i(viíák-3;fe<;hoi) kopoi ireersk. pebcisieriiáii-poi iesj propilén blokk ísopn gaierel··. pol;: eil 0.0-yakd live, píSsiáéipil-kgpfeiddáPsáfeöi ás goikviriíkíieeláriPói álló g’-gfr kópéiig»!, eeilaksz-es goiióierek, oasa péidóol pki; aA igr<>ps i--;ΐäepiee i iolözsais?s;S. hídrisaipropibaiSíiieeliokiZ: hídeasiprepii-eeHiikiz, ebgi idei hr k >z, iódrösiedk ied lieai le ióz, i-idrosieril-seiiiilóz. iridrosieiü-eelkiiöz-aáórái es hidrosisiil-ei iisegeièz, íiróersiprópii' ieedieeiidióz-aesesíAzriksiaák i:birezipropi!-rsieiiioeirtdbz-'báiát. karbesaasiil-eiiieeliolóz, óeiieióz-aeebií'iíaiék sei a kiv-seage-s/aia ίοόΐ. h klrrzsii sropli-pie;; te·.: 1 irsiez-agebibi1s-iái.. rsiisko-aeoi.e-aieseiiiidk hídresiprepii-iaeoiedkaez-aeeizi-OsaA-iaek ás kíi-boziíae-d-sBÍkilóz-aserár-bri-irái, 4; Az à-a igéoygöibök öári-iélyike szeríoti sziked diszperzió, alak a diszperziós goiimer a irreíi Iák rifeav \l '< ' \ K S ' A ' '
  2. 5. Az. k-3. igéisypo-kok bárróeisdke szeried szilárd diszperzió, agöi a diszperziós períd-er a h iáiresíprepi ka-eóleei ialoz fi alá;. ó. Az kb igérízgegiok iAraakaxe szr-o-bi szilárd diszperzió, sbei a diszperziós peiáoer a ss-ik-ke-íícsíár-fraiók
  3. 7. Az A3. ipdéppgsííois bar-oc i y ike szeried szilárd diszperzió, alkd a diszperzi-ás peiiraer is kókáikezdk közöl válaszkob viiblpidselkafiMíólaeaíás koppiíróer ás iíidröxipropibinsiíiseikpóz, vagy ezák keverékéé \ ' < ' . ' ί ί V i ia S ' i i r 1 , < SS a 1 ! i a V : a : ip i i'i'Ó i ί si iiVV ! i: i Í3S 0· á- ii Opo 1 1 -1.-00 9; Az i". igáevpefiiók bârméîÿike szeriéi! szilárd dlszpeizió, abel a diszperziós polbeer ä: ' ' 'M' í Al '. ! ό ids Az i-9, igénvpoftspk sáoeeiyike szeried százra díszperzka abel az káAíkípí .ikápriazeieikg-ippiridia· "..dozii..Asnsb;lead}-Aó-yk'k.ib;:;sdi· i.s ...iPadrizeazei s- dis iisizcio: -1.0-0:.:0:::: a diszperziós pöiiíóer iönisgspez vs.-zoa·. sasa ki' fid .-. kb. 59 ióóiegáá ibeooyiságöefi van ieleü ki. Az 1-19. igöriygórspsk báreseiyske szeried szilárd diszperzió, ehe! az AA-fk-ói. i J:g}.]irhm')sö( i 3-•dp:rid!::-''.:kizl A..:r;!?iPk:::d;. aeaS.-iakiesie-dd-ddiidasis;···:.’:· á-i: À il >3/O : la- bó-g: :·! a :0 kgaiilóó 8ÖPká girier 1' ibrioáki. A-oda i (,» ik-
  4. 12. A H Sgédypösi Axefinil szilárd diszperzió, edtd az ΛΑ<4ΑΠ,;;,4Ί!ΐΐ;:ζ<?ίθΗ Α'.:;]ί·ίί:·;ί1ΐϊϊ-·7·ί!<ίχί)'3' tieddesü í-;V6-i ··>.··: <? ittipíél * 4, s-d ib Idrtsíesgzrb b; - ; i Ikiítyznl se-4 e- -diene ts iggsiábis 9é7a--z enter 1' iöri-né jó.
  5. 13. GyógyszprPszeK készttstény, yrnely tartslistáz i-L?. igénypitstök hátrertyike sirsG szilárd diszpei-zió; és egy e&amp;gy több gyógyszerésze; lieg Atógé<iitíéó segéóydyégői. 14. A 13- igébypoitt szerbéi gyógyszerészeti kószétrtsény. enni y készitüiesiy egy tntrbnt.s LG Λ bb igéiigpest szériái! gyógyszerészeti készititiény, enteg tyKansszzt; y zóvstkezOket: ils) kit. i - kb. 70 töntgysá szilárd diszperzió yz 1 · ; !· igéisyeysntnk lybrnsAybse szerbit: íb > kb. (.·< 1 - 20 ·öt:··,'gK szétesés? elősegítő ásygg; te) kb 0. ; - 31? ióntegzé tizningée: (0) kit 0,1 - ?0 sOexegbij ssésztesnxzer: se? kb. öj · Ki töiíiégOc keroastysg: és ff) kb. Obi Ά iöíitegzy köíöat?y;j;g
    10. A S3. igénypont szerirei gyógyszetészesi készbrnény, entely Grtáití'azze skövetkezőkéi: bn -V-t-i ; t.z. s grinznie? i ..O-ppr'Ane-bAetn;· bn^Aiteed ;-7·:ό··:,· z.dynvté --bé-öéeörnnvszré -2-if )ksonzo1 in-4,6-d Gm in ; és (it) ísáO'itiiii'-bikss'b&amp;ttsSi 17 Λ Ki, igénypont szérint? gyógyszerészeti késziitziény, smejy saripbttyzza y következőkor: ín ? kb. ! · kb, 7 t? tprnegsó 1 - i 2 igéns .peitittk ónneAs ske szer Ati szélerő diszperziói és fb.) kb, 04 > kb yó tötoegv» nábéiirnKrikariteníé, id a )3-17. igent p-teínk bérnseiyike szeri?bi gyógyszerészeti készbznésy, siet; n szóóré diszperzié> kb 35 - kb. óö tönsegAz 19 Az 1-10. igénypontok béenAyike szentéi sziláid diszperzió betegség kezeieseben történő aikybny zésre,
  6. 30. Szilárd diszperzió yiktdrnyzásrs y 19. iggeypity; szerbit, yigri y betegség z rék, Z : . SZizee ó tszperztrí :?!:·. :!::n.:i,.*; ..!'!. !pttítt *-.Z*..*-'ne . ,ην.Ο ,χ ΓΖ·· <; : η' '.’*· S,;,'/0:-, SSi.ZOt ’··.*'·b: *····' ;>itt· espitb, gyeeter-. epe-, koiorekiális·, idóöryk, ses; kissejtes déder.ik. tpisnyáiriíii'igyrák. föl--nyak; Óygynni, peSefészekntk, tnébták és sgydegzyzt,
  7. 22. Szilárd diszperzió áikítintázásts z 20, zagy 21. ígéitypnyt szerint, aboi e mi: Ssrböz pozitív
HUE12809373A 2011-10-14 2012-10-12 Szilárd diszperzió HUE035247T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161547620P 2011-10-14 2011-10-14
US201261606207P 2012-03-02 2012-03-02

Publications (1)

Publication Number Publication Date
HUE035247T2 true HUE035247T2 (hu) 2018-05-02

Family

ID=47471981

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12809373A HUE035247T2 (hu) 2011-10-14 2012-10-12 Szilárd diszperzió

Country Status (31)

Country Link
US (5) US9457093B2 (hu)
EP (1) EP2765990B1 (hu)
JP (2) JP5944514B2 (hu)
KR (1) KR102000312B1 (hu)
CN (3) CN103998023B (hu)
AU (3) AU2012322039C1 (hu)
BR (2) BR112014009092B1 (hu)
CA (2) CA2852058C (hu)
CL (1) CL2014000930A1 (hu)
CO (1) CO6960547A2 (hu)
CR (1) CR20140228A (hu)
CY (1) CY1119837T1 (hu)
DK (1) DK2765990T3 (hu)
ES (1) ES2650608T3 (hu)
HR (1) HRP20171578T1 (hu)
HU (1) HUE035247T2 (hu)
IL (1) IL232103B (hu)
LT (1) LT2765990T (hu)
ME (1) ME02913B (hu)
MX (1) MX353970B (hu)
MY (1) MY169072A (hu)
NO (1) NO2021029I1 (hu)
PL (1) PL2765990T3 (hu)
PT (1) PT2765990T (hu)
RS (1) RS56608B1 (hu)
RU (1) RU2648448C2 (hu)
SG (1) SG11201401459YA (hu)
SI (1) SI2765990T1 (hu)
TW (3) TWI722189B (hu)
WO (1) WO2013056108A2 (hu)
ZA (1) ZA201606123B (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035247T2 (hu) * 2011-10-14 2018-05-02 Array Biopharma Inc Szilárd diszperzió
EP2766363A1 (en) 2011-10-14 2014-08-20 Array Biopharma, Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions containing them
ES2855142T3 (es) * 2012-03-23 2021-09-23 Array Biopharma Inc Compuestos para la utilización en el tratamiento de las metástasis cerebrales en un paciente con cáncer de mama ErbB2+
CA2917199C (en) * 2013-07-19 2021-08-31 Siga Technologies, Inc. Amorphous tecovirimat preparation
JP2017500343A (ja) * 2013-12-20 2017-01-05 フォスフォレックス，インコーポレーテッド インジルビン固体分散体組成物
RU2019123406A (ru) 2014-02-05 2019-10-03 Мерк Шарп И Доум Корп. Технология приготовления таблеток для cgrp-активных соединений
CA2987867C (en) * 2015-06-09 2023-06-27 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN107126419B (zh) * 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 一种奥贝胆酸片剂及其制备方法
WO2017148391A1 (zh) 2016-03-01 2017-09-08 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
SI3601277T1 (sl) * 2017-03-30 2024-02-29 Merck Patent Gmbh Farmacevtska formulacija
EP3615067A1 (en) 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers
TWI780270B (zh) * 2017-11-28 2022-10-11 靜岡縣公立大學法人 固體分散體
JP7244536B2 (ja) * 2018-04-06 2023-03-22 キャプシュゲル・ベルジウム・エヌ・ヴィ メタクリル酸メチル－メタクリル酸コポリマーからなる低アスペクト比の粒子のための噴霧乾燥方法
CN109942576B (zh) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib及中间体的制备方法
CN111825604A (zh) * 2019-04-16 2020-10-27 宁波药腾医药科技有限公司 一种图卡替尼及其中间产物的合成方法
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
CA3151612A1 (en) * 2019-09-19 2021-03-25 George P. Luke Pyruvate kinase r (pkr) activating compositions
JP2022553041A (ja) 2019-10-21 2022-12-21 シージェン インコーポレイテッド Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法
US20220387618A1 (en) 2019-11-15 2022-12-08 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
AU2020417282B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
PL4084778T3 (pl) 2019-12-30 2024-03-04 Deciphera Pharmaceuticals, Llc Formulacje amorficznych inhibitorów kinazy i sposoby ich zastosowania
EP4157257A1 (en) 2020-05-29 2023-04-05 Seagen Inc. Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy
IL300052A (en) 2020-07-29 2023-03-01 Seagen Inc Methods for treating HER2-positive cancer with tocatinib in combination with transtuzumab, a taxane and a VEGFR-2 antagonist
CN115340541B (zh) * 2022-07-01 2024-01-30 上海艾洋化学科技有限公司 一种妥卡替尼中间体的制备方法
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
CN115650977A (zh) * 2022-10-09 2023-01-31 广东润兴生物科技有限公司 一种妥卡替尼的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
CA2431322A1 (en) * 2000-12-11 2002-06-20 Eiji Nara Medicinal compositions having improved absorbability
AU2002221096A1 (en) * 2000-12-11 2002-06-24 Takeda Chemical Industries Ltd. Medicinal compositions improved in solublity in water
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CN103772373B (zh) 2003-08-14 2017-06-09 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
GB0321648D0 (en) 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
BRPI0509381A (pt) * 2004-04-08 2007-09-18 Wyeth Corp dispersão sólida, métodos de preparar a dispersão sólida, de tratar um mamìfero tendo uma doença ou sìndrome associadas com a deficiência ou o excesso de estrogênio, uma doença ou distúrbio associados com a proliferação ou desenvolvimento anormal de tecidos endometrais, de tratar cáncer de mamas de um mamìfero, e uma mulher pós-menopáusica quanto a um ou mais distúrbios vasomotores, de reduzir colesterol, e de inibir perda óssea em um mamìfero, composição, forma de dosagem, e, uso de uma dispersão sólida
BR122018075851B1 (pt) * 2005-11-15 2022-01-11 Array Biopharma Inc Compostos relacionados ao tratamento de doença hiperproliferativa e processos para preparar compostos
US9101617B2 (en) * 2007-04-20 2015-08-11 Daido Chemical Corporation Base for dry solid dispersion, solid dispersion containing the base, and composition containing the dispersion
CN101702878B (zh) 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 可溶性差的药物的药物组合物
JP2010540460A (ja) * 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ，インク． ＣＯＸ‐２阻害薬と抗ＨＥＲ２［ＥｒｂＢ２］抗体の混合物又はＣＯＸ‐２阻害薬とＨＥＲ２［ＥｒｂＢ２］受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療
WO2009135799A2 (en) * 2008-05-05 2009-11-12 Abbott Gmbh & Co. Kg Method for evaluating the solubility of a crystalline substance in a polymer
EP2158912A1 (en) * 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2253306A1 (en) * 2009-05-18 2010-11-24 Royal College of Surgeons in Ireland Orodispersible dosage forms containing solid drug dispersions
EP2766363A1 (en) 2011-10-14 2014-08-20 Array Biopharma, Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions containing them
HUE035247T2 (hu) * 2011-10-14 2018-05-02 Array Biopharma Inc Szilárd diszperzió
ES2855142T3 (es) 2012-03-23 2021-09-23 Array Biopharma Inc Compuestos para la utilización en el tratamiento de las metástasis cerebrales en un paciente con cáncer de mama ErbB2+

Also Published As

Publication number Publication date
TW202131902A (zh) 2021-09-01
CA3114454A1 (en) 2013-04-18
WO2013056108A2 (en) 2013-04-18
TW201728323A (zh) 2017-08-16
AU2017210499B2 (en) 2019-01-24
CY1119837T1 (el) 2018-06-27
CA2852058A1 (en) 2013-04-18
EP2765990A2 (en) 2014-08-20
AU2012322039C1 (en) 2021-04-29
AU2019200243A1 (en) 2019-01-31
EP2765990B1 (en) 2017-09-06
RU2648448C2 (ru) 2018-03-26
US9457093B2 (en) 2016-10-04
AU2019200243C1 (en) 2021-04-29
BR112014009092A2 (pt) 2017-04-18
US20210220361A1 (en) 2021-07-22
LT2765990T (lt) 2018-01-25
AU2017210499C1 (en) 2021-04-29
KR102000312B1 (ko) 2019-07-15
US20190275043A1 (en) 2019-09-12
ZA201606123B (en) 2021-05-26
WO2013056108A3 (en) 2013-06-27
TWI722189B (zh) 2021-03-21
TWI788733B (zh) 2023-01-01
KR20140075798A (ko) 2014-06-19
BR112014009092B1 (pt) 2022-01-18
HRP20171578T1 (hr) 2017-12-01
DK2765990T3 (da) 2017-11-13
IL232103B (en) 2018-11-29
CA3114454C (en) 2022-11-29
MY169072A (en) 2019-02-12
ME02913B (me) 2018-04-20
BR122020010643B1 (pt) 2022-05-17
MX353970B (es) 2018-02-07
CN103998023B (zh) 2018-06-15
JP2014528484A (ja) 2014-10-27
CR20140228A (es) 2014-08-21
ES2650608T3 (es) 2018-01-19
AU2012322039A1 (en) 2014-06-05
AU2012322039B2 (en) 2017-08-17
CN114886853A (zh) 2022-08-12
CN108498465B (zh) 2022-05-17
AU2017210499A1 (en) 2017-08-17
RU2014119283A (ru) 2015-11-20
CL2014000930A1 (es) 2014-07-18
MX2014004551A (es) 2015-02-12
SG11201401459YA (en) 2014-07-30
TW201330876A (zh) 2013-08-01
IL232103A0 (en) 2014-05-28
US20230097309A1 (en) 2023-03-30
TWI594769B (zh) 2017-08-11
US20140296267A1 (en) 2014-10-02
RS56608B1 (sr) 2018-02-28
JP5944514B2 (ja) 2016-07-05
NO2021029I1 (no) 2021-07-09
PL2765990T3 (pl) 2018-01-31
CA2852058C (en) 2021-06-01
US20170136022A1 (en) 2017-05-18
AU2019200243B2 (en) 2020-06-11
NZ624942A (en) 2016-06-24
CN103998023A (zh) 2014-08-20
CN108498465A (zh) 2018-09-07
CO6960547A2 (es) 2014-05-30
JP2016027062A (ja) 2016-02-18
PT2765990T (pt) 2017-11-14
SI2765990T1 (sl) 2017-11-30

Similar Documents

Publication Publication Date Title
AU2019200243B2 (en) Solid dispersions of a erb2 (her2) inhibitor
JP7258924B2 (ja) ブルトンチロシンキナーゼの阻害剤を含む剤形組成物
EP3400943B1 (en) Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer
NZ624942B2 (en) Solid dispersions of a erb2 (her2) inhibitor